title: Reply: Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery.
authors.affiliation: Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Networked Biomedical Research Centre for Hepatic and Digestive Diseases (CIBERehd), Hospital Clinic Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Carrer Villarroel 170, 08036 Barcelona, Spain.
authors.forename: Alejandro
authors.initials: A
authors.lastname: Forner
authors.affiliation: Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte Marguerite, 13009 Marseille, France.
authors.forename: Marine
authors.initials: M
authors.lastname: Gilabert
authors.affiliation: Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Networked Biomedical Research Centre for Hepatic and Digestive Diseases (CIBERehd), Hospital Clinic Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Carrer Villarroel 170, 08036 Barcelona, Spain.
authors.forename: Jordi
authors.initials: J
authors.lastname: Bruix
authors.affiliation: Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte Marguerite, 13009 Marseille, France.
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Raoul
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D006801:Humans; D008113:Liver Neoplasms / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents